We are live on ! Find out more
GDTC icon

CytoMed Therapeutics
GDTC

2 hedge funds and large institutions have $21.5K invested in CytoMed Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more capital invested

Capital invested by funds: $20.7K → $21.5K (+$802)

0% more funds holding

Funds holding: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.01% less ownership

Funds ownership: 0.05% → 0.04% (-0.01%)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$11.4K
2
TRCT
Tower Research Capital (TRC)
New York
+$3.32K

Top Sellers

Rank Fund Capital Flow
1
SSG
Summit Securities Group
New York
-$19K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$17.1K +$11.4K +3,023 +634%
TRCT
2
Tower Research Capital (TRC)
New York
$4.32K +$3.32K +882 New
SSG
3
Summit Securities Group
New York
– -$19K -5,407 Closed

GDTC Hedge Fund Activity: Q4 2023 in Review

2 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q4 2023, worth a combined $21.5K — up 3.9% from $20.7K a quarter earlier.

Fund positioning in GDTC was balanced in Q4 2023: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, adding an estimated $11.4K. The largest seller was Summit Securities Group, exiting entirely with an estimated $19K sold.

  • 2 institutional investors held CytoMed Therapeutics (GDTC) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $21.5K of CytoMed Therapeutics stock for Q4 2023, up 3.9% quarter-over-quarter.
  • 1 fund opened new CytoMed Therapeutics positions in Q4 2023 and 1 closed out, a net change of 0 holders.
  • The largest CytoMed Therapeutics buyer in Q4 2023 was UBS Group, an estimated $11.4K added.
  • The largest CytoMed Therapeutics seller in Q4 2023 was Summit Securities Group, an estimated $19K sold.

Based on aggregated 13F filings for Q4 2023.